Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Has Average Target Price of $38.50

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $38.50.

A number of research analysts have recently issued reports on the company. Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a report on Friday, September 25th. HC Wainwright reissued a “buy” rating on shares of Aligos Therapeutics in a research report on Monday, August 10th. Finally, Weiss Ratings cut Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th.

Hedge Funds Weigh In On Aligos Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its holdings in Aligos Therapeutics by 1,652.8% in the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after purchasing an additional 216,646 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Aligos Therapeutics by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after buying an additional 15,006 shares in the last quarter. SummitTX Capital L.P. boosted its holdings in shares of Aligos Therapeutics by 6.7% in the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after buying an additional 9,375 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its holdings in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.

Aligos Therapeutics Stock Down 10.2%

Shares of ALGS stock opened at $4.51 on Friday. The firm has a market cap of $28.16 million, a price-to-earnings ratio of -0.62 and a beta of 2.43. Aligos Therapeutics has a 52-week low of $3.98 and a 52-week high of $13.69. The company’s 50 day moving average is $5.37 and its 200 day moving average is $6.19.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.95. The company had revenue of $27.78 million during the quarter, compared to analyst estimates of $24.68 million. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%. Analysts anticipate that Aligos Therapeutics will post -6.81 EPS for the current fiscal year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.